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Summary Pregabalin is a novel anticonvulsive and analgesic drug that has been
marketed in Europe for more than a year. The typical side effects are dizziness,
somnolence and weight gain. We present a patient who, after unintended rapid up-
titration of pregabalin, experienced psychotic symptoms associated with rhythmic
EEG-changes resolving completely after discontinuation of pregabalin and benzodia-
zepine administration.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Pregabalin is effective in patients with partial sei-
zures, neuropathic pain and generalized anxiety
disorders in several placebo-controlled trials. Som-
nolence and dizziness are the most frequent side
effects among patients receiving pregabalin. Psy-
chiatric symptoms have not been reported to date as
typical side effects, and there is no evidence for
proconvulsive effects, even in patients receiving
high dosages.1 We describe a patient with chronic
neuropathic pain who developed a psychotic epi-
sode associated with rhythmic epileptiform EEG-
changes after the initiation of pregabalin treat-
ment.* Corresponding author. Tel.: +49 251 8348196;
fax: +49 251 8348181.
E-mail address: kelling@uni-muenster.de (C. Kellinghaus).
1 Both authors contributed equally to this paper.
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A 44-year-old female patient was admitted to our
department because of progressive spasticity of
unknown etiology. The symptoms started 5 years
ago with increasing numbness in her hands and legs.
Then the patient experienced neuropathic pain in
her hands, feet, and neck. At admission, the neu-
rological examination revealed asymmetric spasti-
city in all four limbs, more on the right than the left.
There were bilateral Babinski’s signs as well as distal
hypesthesia and allodynia in the legs.
The MRI examination of the brain and spine was
normal, except for two old lesions on the right side
of the putamen and the ventral side of the left
lateral ventricle. Analysis of the cerebrospinal fluid
(CSF) showed mild pleocytosis and mildly elevated
protein level. Antibodies for borreliosis were not
detectable. Electrodiagnostic studies revealed a
predominantly sensory, distal symmetrical axonal. Published by Elsevier Ltd. All rights reserved.
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chronic denervation on the electromyographic
examination. The EEG was normal, without slowing
or epileptiform discharges (Fig. 1a). Initially she was
treated with oxycodone 160 mg per day and ibupro-
fen 800 mg per day without sufficient reduction of
the neuropathic pain. Because of the CSF findings,
additional antibiotic therapy with ceftriaxone
sodium i.v. was initiated but had no effect on the
symptoms. Pain modulating therapy with amitrypti-
line (50 mg per day) was initiated and was well-
tolerated. In addition, we recommended pregabalin
starting with 150 mg per day and increasing in steps
of 150 mg every 4 days. The patient was discharged
with a prescription for pregabalin. Besides baclofen
(30 mg per day) and flunitrazepam (1 mg per day),
no further drug affecting the CNS was administered.
Two days later, the patient started taking
600 mg pregabalin per day without any titration.
Subsequently, she became somnolent and dev-
eloped psychotic symptoms consisting of affectiveFigure 1 (a) Normal EEG 2 weeks before onset of pregabalin
episode: generalized slowing, epileptiform discharges in bot
after the intravenous administration of 4 mg of lorazepam: r
right posterior head region; and (d) EEG 2 weeks after onset
symptoms: normal background activity.disturbance, visual hallucinations, agitation and
paranoid ideation. There was no previous history
of psychotic symptoms. She was admitted to our
intensive care unit by her general practitioner 3
days after she had started taking pregabalin. On
admission, she was disoriented, agitated and
experienced visual hallucinations. There were no
other abnormalities in the general physical and
neurological examination. The EEG showed rhyth-
mic slowing and epileptiform discharges in both
posterior head regions (Fig. 1b) that disappeared
after the intravenous administration of 4 mg of
lorazepam (Fig. 1c). The CSF revealed no cells, a
slightly elevated protein level (511 mg/l), and no
evidence for the local synthesis of antibodies.
Blood-count, extended blood-chemistry including
electrolytes, liver enzymes and blood urea nitrogen
were normal. The pregabalin plasma level was
7.7 mg/ml on admission and 1.9 mg/ml 12 h later.
The patient was diagnosed with pregabalin-asso-
ciated ictal and postictal psychosis. We discontinuedtreatment; (b) EEG 2 days after the onset of the psychotic
h posterior head regions, maximum on the right; (c) EEG
estored background activity, with intermittent slowing in
of the psychotic episode, with resolution of the clinical
210 I. Olaizola et al.pregabalin and treated her with lorazepam for 2
weeks. During this time, the patient gradually
recovered and the EEG became normal again
(Fig. 1d).Discussion
The patient suffered from a sudden psychotic epi-
sode immediately after rapid titration of a relatively
large dose of pregabalin. The episode was asso-
ciated with rhythmic and epileptiform EEG changes
that resolved after the administration of lorazepam.
The symptoms disappeared within 2 weeks of antic-
onvulsant treatment and did not recur again. The
clinical examination, routine blood tests and CSF
analysis did not show evidence for an alternative
explanation of the patient’s symptoms. The close
temporal relationship between the start of prega-
balin therapy and the onset of the symptoms as well
as the singularity of the episode suggest a causative
role for pregabalincrucial role of pregabalin.
Anticonvulsant-associated psychotic symptoms
are relatively rare.Vigabatrin may induce or worsen
psychosis and depression.2 Topiramate may induce
both psychosis and depression, but these are less
likely to occur at the currently recommended start-
ing doses.2 Gabapentin most likely has relatively
little effect on behaviour but may exacerbate beha-
vioural problems in some children with pre-existing
difficulties.2 In addition, there is a single case report
on a gabapentin-induced paradoxical exacerbation
of psychosis in a patient with schizophrenia.3
The rhythmic EEG changes and newly developed
epileptiform discharges that subsided after antic-
onvulsant treatment suggest an epileptic nature of
the episode. The paradoxical effects of anticonvul-
sants are well-recognized. They usually occur spor-
adically and in association with overdose or
intoxication4 but may also occur at normal doses
and drug levels.5 In our case, the patient took a high
but normal dose, and her serum drug levels were
within the normal range seen in the drug-approval
studies.6 However, the patient did not gradually
increase the daily dose but immediately took the
target dose of 600 mg per day. The sudden admin-
istration of a relatively high drug dose may have
played a crucial role.
The pathophysiological mechanism of the
patient’s symptoms remains unclear. Although preg-
abalin is structurally related to GABA, it does not
interact with either GABAA or GABAB receptors, it isnot converted to GABA or to a GABA agonist, and it is
not an inhibitor of GABA uptake or degradation.7
Pregabalin (as well as gabapentin) interacts with an
auxiliary subunit (the alpha2-delta subunit) of pre-
synaptic voltage-gated calcium channels in the CNS.
Potent binding at this site attenuates depolariza-
tion-induced calcium influx at nerve terminals, with
a subsequent reduction in the release of excitatory
neurotransmitters, including glutamate, noradrena-
line, and substance P.7 In predisposed persons, a
sudden increase of pregabalin plasma levels might
result in relative over-attenuation of inhibitory sys-
tems, and thus in paradoxical over-synchronization.
However, there is no data available yet to elucidate
this phenomenon.
Pregabalin is an effective anticonvulsant and
analgesic drug. In the vast majority of patients,
central nervous system side effects are rare, mild
and transient in nature.1 However, physicians should
be aware that in some patients, even a normal dose
of pregabalin may be associated with psychotic
symptoms. More data is needed to estimate the risk
and relevant risk factors for this phenomenon.Acknowledgement
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